German Adjuvant Intergroup Node-positive Study (GAIN): a phase III trial comparing two dose-dense regimens (iddEPC versus ddEC-PwX) in high-risk early breast cancer patients

Erstveröffentlichung
2017Authors
Moebus, Volker
von Minckwitz, Gunter
Jackisch, Christian
Lueck, Hans-Joachim
Schneeweiss, Andreas
Wissenschaftlicher Artikel
Published in
Annals of Oncology ; 28 (2017), 8. - S. 1803-1810. - ISSN 0923-7534. - eISSN 1569-8041
Link to publication
https://dx.doi.org/10.1093/annonc/mdx203Institutions
UKU. Klinik für Frauenheilkunde und GeburtshilfeSubject headings
[Free subject headings]: adjuvant chemotherapy breast cancer | high-risk early breast cancer | node-positive breast cancer | dose-dense chemotherapy | intense dose-dense chemotherapy | capecitabine | chemotherapy | epirubicin | cyclophosphamide | docetaxel | paclitaxel | standard | survival | efficacy | women[DDC subject group]: DDC 610 / Medicine & health
Metadata
Show full item recordThis could also interest you:
-
Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors- An analysis of 2765 patients from neoadjuvant clinical trials
Villegas, Sonia L. et al. (2021)Wissenschaftlicher Artikel
-
Breast cancer risk inBRCA1/2mutation carriers and noncarriers under prospective intensified surveillance
Engel, Christoph et al. (2020)Wissenschaftlicher Artikel
-
Does Non-Placement of a Drain in Breast Surgery Increase the Rate of Complications and Revisions?
Ebner, Florian K. et al. (2013)Wissenschaftlicher Artikel